



Contact:

Dr. Misha Plam

President & CEO

T: (303) 641-3669

misha.plam@amidebio.com

www.amidebio.com

Vincent P. Mihalik, former Amylin executive, joins the Board of Directors of AmideBio

BOULDER, CO, April 15, 2014 – AmideBio, LLC, a privately held biopharmaceutical company leveraging its proprietary manufacturing technology to generate a pipeline of therapeutics including a novel Thermostable Insulin, is pleased to announce that Vincent P. Mihalik has joined the company's Board of Directors.

Vince Mihalik was Senior Vice President, Sales and Marketing, and Chief Commercial Officer of Amylin Pharmaceuticals, Inc. prior to its \$7 billion acquisition by Bristol-Myers Squibb in 2012. During his tenure, Mr. Mihalik directed all commercial alliance activities, including a partnership with Eli Lilly on Exenatide, a GLP-1 agonist for the treatment of diabetes. Mr. Mihalik also led the launch and commercialization team for the once weekly Exenatide formulation, Bydureon, which was approved by the FDA in 2012.

"We are delighted to welcome Vince Mihalik to the AmideBio team as we move our initial product candidates for treating diabetes and other diseases through preclinical evaluation. Vince's decision to join AmideBio will not only enable the company to take advantage of his intimate knowledge of the diabetes market, but will also allow us to apply Vince's experience with structuring and managing commercial ventures to our newly developing relationships with pharma partners," said Dr. Misha Plam, AmideBio's President and CEO.

Vince Mihalik added that "I am excited to join the AmideBio Board of Directors. Being able to participate as a Board member on AmideBio's exciting technology platform is hugely satisfying. There are so many diseases that can benefit from this technology, not just in diabetes but with many other unmet patient needs. AmideBio is definitely pioneering new approaches in biochemistry."

Mr. Mihalik's distinguished career in the pharmaceutical industry spans nearly 40 years. Prior to joining Amylin, he was VP of Diabetes Product Development and Commercialization at Eli Lilly and Company. Mr. Mihalik also held senior executive positions in development and commercialization at Roche Diagnostics, Boehringer Mannheim, and Baxter Healthcare. He is the holder of a B.S. degree in Biology from Pennsylvania State University and a Masters in Management from Northwestern University.

About AmideBio:

AmideBio, based in Boulder, CO, is a biotechnology company leveraging its proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides and build a pipeline of novel biotherapeutics. AmideBio's proprietary technology enables the rapid and economical manufacture of pure peptides of any length. This innovative technology combines recombinant and chemical methods, eliminates many of the inefficient and costly steps of processes that rely only on one or the other approach, results in fewer batch inconsistencies and less waste generation. Such advantages offer AmideBio multiple opportunities to offer technology and cost benefits to the pharmaceutical and biotech industry. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at metabolic, inflammatory and neurodegenerative diseases.

- ENDS -